慢性心力衰竭(chronic heart failure,CHF)是指各种原因引起的心脏结构和功能的衰竭,使心输出量绝对或相对减少,不能满足机体的代谢需要,从而引起典型症状或体征的临床综合征。近年来,β受体阻滞剂在CHF的治疗中逐渐受到重视。长期应用β受体阻滞剂可明显改善CHF患者预后,尤其是第三代β受体阻滞剂卡维地洛能显著降低CHF患者病死率~([1-2])。因此,卡维地洛被认为是治疗CHF的首选β受体阻滞 Chronic heart failure (CHF) refers to the failure of cardiac structure and function caused by various causes, which can definitely or relatively reduce the cardiac output, can not meet the metabolic needs of the body and lead to clinical syndromes of typical symptoms or signs . In recent years, β-blockers have received increasing attention in the treatment of CHF. Long-term use of β-blockers can significantly improve the prognosis of CHF patients, especially the third-generation β-blocker carvedilol can significantly reduce the mortality of CHF patients (1-2). Therefore, carvedilol is considered the first choice of beta block in the treatment of CHF